ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Ab Science

Ab Science (AB)

0.785
-0.005
(-0.63%)
Closed December 03 10:30AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.785
Bid
0.78
Ask
0.801
Volume
23,024
0.776 Day's Range 0.80
0.77 52 Week Range 4.465
Market Cap
Previous Close
0.79
Open
0.79
Last Trade
3
@
0.785
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
36,339
Shares Outstanding
52,071,069
Dividend Yield
-
PE Ratio
-3.39
Earnings Per Share (EPS)
-0.23
Revenue
970k
Net Profit
-11.99M

About Ab Science

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Paris, Paris, Fra
Founded
-
Ab Science is listed in the Pharmaceutical Preparations sector of the Euronext with ticker AB. The last closing price for Ab Science was 0.79 €. Over the last year, Ab Science shares have traded in a share price range of 0.77 € to 4.465 €.

Ab Science currently has 52,071,069 shares outstanding. The market capitalization of Ab Science is 41.14 € million. Ab Science has a price to earnings ratio (PE ratio) of -3.39.

AB Latest News

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN...

AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose

AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS...

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB’S...

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL...

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE...

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 17 October, 2024...

AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science

AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science          COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS AU PREMIER SEMESTRE...

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities          PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS...

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

         PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIOD Clinical development Masitinib platform: Ongoing re-examination by...

AB Science annonce avoir réalisé le règlement livraison de sa dernière augmentation de capital de 5,0 millions d’euros

AB Science annonce avoir réalisé le règlement livraison de sa dernière augmentation de capital de 5,0 millions d’euros COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR REALISE LE REGLEMENT LIVRAISON...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0151.948051948050.770.8430.77262220.80263709DE
4-0.225-22.27722772281.011.020.77404950.86323457DE
12-0.205-20.70707070710.991.0620.77363390.94574428DE
26-0.315-28.63636363641.11.70.77655421.14558508DE
52-1.915-70.92592592592.74.4650.77986162.19130691DE
156-11.275-93.490878938612.0613.340.77952704.63110648DE
260-4.795-85.93189964165.5821.750.771455618.561332DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ALCYBCybergun
0.0002 €
(100.00%)
10.06M
ALVETEGEIRO Pharma
0.124 €
(58.97%)
481.8k
ALDVAlliance Developpement Capital Siic
0.074 €
(32.14%)
6k
MLSRPSpeed Rabbit Pizza
8.20 €
(30.16%)
19
MLSEQSequa Petroleum NV
0.011 €
(29.41%)
12k
MLCOTCoretech 5
0.01 €
(-41.18%)
200
ATOAtos SE
0.495 €
(-32.65%)
17.92M
AFMEAffluent Medical
1.20 €
(-21.05%)
21.92k
ALBIOBiosynex
2.095 €
(-18.32%)
26.9k
TRACTTeract SA
1.03 €
(-15.23%)
76.91k
BCPBanco Comercial Portugues SA
0.4457 €
(2.20%)
44.64M
ALNEVNeovacs
0.0003 €
(0.00%)
33.59M
ATOAtos SE
0.495 €
(-32.65%)
17.92M
ALCYBCybergun
0.0002 €
(100.00%)
10.06M
ORAOrange.
9.706 €
(-2.99%)
9.65M

Discussion

View Full Feed
NickyCapone NickyCapone 3 minutes ago
https://share.icloud.com/photos/0bbZF_t9tlGxTHW381mAjW_Ow
AMC
PonkenPlonken PonkenPlonken 3 minutes ago
Thank you for sharing!
They seem to believe this makes it to market in CRC is my read.
NVCR
coolhandluke88 coolhandluke88 3 minutes ago
If you voted for Kamala enough said. You better just get out of the markets and not prosper this next 4 years. Hilter are you seriously peddling that bs. Such week minds.
GRST
ANTI-BAGHOLDER ANTI-BAGHOLDER 3 minutes ago
Must be the peeps waiting on the 20 year audit, or the best chart in the OTC, or HUGE news coming?

Has to be one of those, no?
SPZI
Serpico2005 Serpico2005 3 minutes ago
I'm asking the same questions, it seems people are losing patience with this. 
SPZI
flipper44 flipper44 4 minutes ago
Market Makers are writing their own damages epitaph.
NWBO
Jetmek_03052 Jetmek_03052 4 minutes ago
It would be just like Linda to file the application for the QB level, while knowing that the company's governance situation made them ineligible for it.

That way, she could put out a nice fluffy update, claiming that DBMM was "working" with the OTCM to uplist to the QB level. She wou
DBMM OTCM
Gmenfan Gmenfan 4 minutes ago
The Governors and Mayors that want to hinder ICE may want to take a different stance!
Rodney5 Rodney5 4 minutes ago
FFFacts, as you said be concise and clear. There is not an unlimited amount of funding available from the Treasury.

The difference in what the Treasury had authority to do and what actually happened during conservatorship as it relates to Treasury's actions, simplified.
FNMA
pzottkpz pzottkpz 4 minutes ago
⏲️

💲TLRY
TLRY
AJH92 AJH92 4 minutes ago
Update - December 3: "Check out the article from Fox News Digital. They reached out to our CEO, Tony Torgerud a couple weeks ago with some questions.

https://foxnews.com/food-drink/beer-taste-great-there-health-benefits-associated

#doinitright #themissingelemwntyounee
APRU
delerious1 delerious1 5 minutes ago
CHARBONE HYDROGEN CORPORATION ("CH")
BULLETIN TYPE: Shares for Debt
BULLETIN DATE: October 2, 2024
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing the Company's proposal to issue 1,800,000 common shares at a deemed price of $0.10 per comm
Werbe Werbe 5 minutes ago
Mexedia owns Phonetime and Matchcom, theyre obligors on the 44 million loan. They are paying a million a month to pay this off. If they default, credit facility takes all Mexedia assets.

A default under our $45 million credit facility agreement could result in our lender foreclosing
RDAR
delerious1 delerious1 5 minutes ago
CHARBONE HYDROGEN CORPORATION ("CH")
BULLETIN TYPE: Shares for Debt
BULLETIN DATE: October 2, 2024
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing the Company's proposal to issue 1,800,000 common shares at a deemed price of $0.10 per comm
CHHYF
solidgold solidgold 5 minutes ago
MANIPULATION.
NBRI
Gmenfan Gmenfan 6 minutes ago
I wonder what the Governors and Mayors that are going to hinder ICE think about the ruling?
georgie18 georgie18 6 minutes ago
Thanks Pink...🥳
oldstocks oldstocks 6 minutes ago
Because i told everyone on all the boards to boycott the stock until the company posts more often and more details.

That means, no selling, no buying

That also means for the company not to issue any new shares because we are not buying until they inform us on LinkedIn
AFFU
FooBarAndGrill FooBarAndGrill 7 minutes ago
Loaded at $38!!! Oh really?
https://investorshub.advfn.com/uimage/uploads/2024/12/3/ilnlxScreenshot_2024-12-03_11.17.17_AM.png
SMCI
jimmybob jimmybob 7 minutes ago
PTON back over 10
PTON
coolhandluke88 coolhandluke88 7 minutes ago
Keep drinking the Kool aid you idiot. Jim Jones needed idiots like you. Biden wasn't going to pardon Hunter too. lol
GRST

Your Recent History

Delayed Upgrade Clock